期刊
INTERNATIONAL JOURNAL OF HEMATOLOGY
卷 112, 期 5, 页码 725-727出版社
SPRINGER JAPAN KK
DOI: 10.1007/s12185-020-02918-6
关键词
Eltrombopag; Chemotherapy-induced thrombocytopenia; MYH9-RD; Thrombocytopenia
类别
资金
- Fondazione Umberto Veronesi
Chemotherapy is the mainstay of treatment for advanced pancreatic cancer however, due to possible myelotoxicity, it is used with caution in patients with thrombocytopenia, especially when severe. TPO-receptor agonists have been employed for chemotherapy-induced thrombocytopenia, however treatment with TPO-receptor agonists to allow chemotherapy in patients with inherited thrombocytopenia has not been reported so far. We report the first successful use of eltrombopag to prevent chemotherapy-induced thrombocytopenia in a patient withMHY9-related disorder and pancreatic cancer. Treatment with eltrombopag allowed to attain a safe and stable platelet count for several months sufficient to permit chemotherapy and to allow the patient to undergo endoscopic placement of a biliary stent with no bleeding complications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据